Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CONTRACEPTIVE DEVICES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 523 records · Page 29Linked to original sources
PubMed1981

[Electrophoretic study on the changes of serum protein fractions in Korean women--the effects of age, oral contraceptive, and intrauterine contraceptive device (author's transl)].

The serum levels of total protein, albumin, and electrophoretic fractions from 610 Korean women, 21-50 years, were measured to determine their relation to age, and the effects of oral contraceptives (OCs) (Norinyl), and Lippes Loop IUD. In normal women, total protein and albumin concentrations significantly decreased with age. Alpha2 and gamma globulin concentrations were decreased after the age of 40, but the statistical significance was low. Significant decreases in total protein and albumin concentrations were observed in OC and IUD users, and rapid decrease in total protein was observed in OC users rather than in IUD users. Beta globulin was slightly increased in both groups, and gamma globulin was decreased in OC users. No significant changes in alpha1 and alpha2 globulin concentrations were noted in either group.

Age Factors↗
PubMed1990

[Characteristics of the clinical course of acute adnexitis in patients using intrauterine contraceptive devices].

Clinical presentations of acute inflammatory adnexae diseases (AIAD) have been delineated in 127 patients who were users of intrauterine contraceptives (IUC). It was found that these diseases occurred with severe clinical symptoms in IUC users and were associated with prominent morphologic lesions: pyosalpinx and suppurative ovarian inflammation in every 2nd case, suppurative endomyometritis in every 3rd and parametritis in every 10th case. To prevent AIAD, the use of IUC should rigorously follow indications and contraindications. The use of IUC ought not be protracted beyond 3 years.

Acute Disease↗
PubMed1999

Lea's Shield contraceptive device: pilot study of its short-term patient acceptability and aspects of use.

OBJECTIVE: To assess the short term patient acceptability and aspects of use of the Lea's Shield(R). DESIGN: Observational study. Ten women were each invited to use the Lea's Shield on 10 occasions and to report their observations and experiences on structured questionnaires after each use. Thus, data on a maximum of 100 uses would become available for analysis. Answers were recorded on numerical scales and in descriptive terms. On conclusion of their study participation, patients and their partners were required to document their overall experience with the product. SETTING AND SUBJECTS: Women aged 18 to 40 years, self-selected from clients attending the Margaret Pyke Family Planning Centre. They had to be in a stable monogamous relationship, gynaecologically healthy, and willing to continue their use of oral contraceptives, IUD, or injectable. MAIN OUTCOME MEASURE: Ability to use the method without formal teaching, assessed after vaginal examination by the investigator at end of first visit. User satisfaction, as expressed in structured questionnaires and by premature withdrawal from trial. RESULTS: Ten women used Lea's Shield on a total of 70 occasions, of which 46(66 per cent) were associated with sexual intercourse. Five subjects withdrew from the trial prematurely on account of discomfort to either or both partners (four), and recurrent cystitis (one). At the enrolment visit, all but one woman inserted the device correctly without formal teaching, but there was considerable inter-patient variation in their responses concerning ease of insertion/removal, and comfort during subsequent uses. CONCLUSIONS: These preliminary observations suggest that the Lea's Shield may be acceptable to a highly select minority of women. However, much more research is required to permit a reliable assessment of its acceptability to the wider public. The product's potential for causing pain and discomfort also needs further exploration.

Adolescent↗
PubMed1978

Genital actinomycosis and intrauterine contraceptive devices. Cytopathologic diagnosis and clinical significance.

This study from a community hospital documents the relatively frequent occurrence of Actinomyces in 36 women diagnosed by Papanicolaou stained cervicovaginal smears. Actinomyces was identified exclusively in patients wearing an intrauterine or vaginal foreign body (intrauterine devices and pessaries). By using fluorescein isothiocyanate labeled antiserum, the organisms were shown to be Actinomyces israelii in eight randomly selected smears. In five cases Actinomyces was demonstrated in tissues obtained by endocervical and endometrial curettage. Anaerobic microbiologic studies performed in 11 of the 36 cases showed a relatively high rate of recovery of Actinomyces (36.3 per cent) with a yield of four positive cultures. In two cases the isolated organisms were shown to be Actinomyces israelii. In the remaining two cases the exact species of Actinomyces has remained uncertain. Of the 36 patients with smear evidence of Actinomyces, nine (25 per cent) had pelvic inflammatory disease, a rate that appears to be much higher than the already high rate among all intrauterine device users. This observation underscores the importance and clinical significance of the finding of Actinomyces in the vaginal smears of intrauterine device users. Papanicolaou stained cervicovaginal smears provide a relatively easy, inexpensive, fast, and highly specific method for the morphologic diagnosis of Actinomyces and allows us to recognize at a relatively early stage a group of patients who are potentially at risk for the development of pelvic inflammatory disease and its associated more severe complications. The hope is that prompt identification of Actinomyces in cervicovaginal smears can help to prevent the more serious infectious complications in intrauterine device users.

Actinomyces↗